<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106119</url>
  </required_header>
  <id_info>
    <org_study_id>050119</org_study_id>
    <secondary_id>05-DK-0119</secondary_id>
    <nct_id>NCT00106119</nct_id>
  </id_info>
  <brief_title>Thyroid and Glucose and Energy Metabolism</brief_title>
  <official_title>Peripheral Thyroid Hormone Conversion and Glucose and Energy Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine how two thyroid preparations-levothyroxine (T4) and liothyronine
      (T3)-affect fat and cholesterol metabolism, blood sugar regulation, and thyrotropin secretion
      in patients who have had their thyroid gland removed. Results of the study may help in the
      development of better therapies to optimize blood sugar and cholesterol levels in some
      patients.

      Patients 18 years of age or older who have had most or all of their thyroid gland removed and
      are taking long-term thyroid hormone medication may be eligible for this study after
      screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid hormone action plays an important role in the regulation of many physiologic
      processes, among them glucose and lipid metabolism. Interestingly, the clinical presentation
      of thyroid dysfunction is extremely variable, with relatively poor correlation between
      circulating hormone levels and clinical features. This finding suggests that the local,
      intracellular concentration of the active hormone liothyronine (T3), regulated by peripheral
      conversion of the pro-hormone levothyroxine (T4), is an important determinant in the
      maintenance of the thyroidal homeostasis.

      The aim of the present study is the evaluation of the role of peripheral thyroid hormone
      conversion in the regulation of glucose and lipid metabolism by assessing the differential
      response to T4 or T3 treatment in subjects devoid of endogenous thyroid hormone production.
      T3 administration bypasses peripheral metabolism and therefore will allow us to assess the
      role of the peripheral thyroid hormone conversion in the regulation of the hormone action at
      the end-organ level.

      Fifty hypothyroid subjects will be initially randomized to either of the thyroid hormone
      replacements liothyronine (T3) or levothyroxine (T4) treatment period (one arm cross-over
      design, with treatment sequence randomized), aimed to maintain serum TSH levels greater than
      or equal to 0.5 less than or equal to 1.5 mU/L, indicating full replacement. After a 30-day
      period of steady-state replacement the study subjects will be admitted to the Clinical Center
      and, after a three-day period of stabilization and an overnight fast, will undergo the
      following tests: escalating dose TRH stimulation test, indirect calorimetry, graded exercise
      tolerance test, DEXA scan, and echocardiogram.

      Patients will also undergo skeletal muscle biopsy and subcutaneous adipose tissue biopsy and
      microdialysis, as well as a two-step euglycemic hyperinsulinemic clamp with measurement of
      splanchnic gluconeogenesis. Fasting venous blood samples will be collected for the
      determination of the parameters of lipid, glucose and energy metabolism.

      After discharge, the patients will switch to the other form of thyroid hormone replacement
      therapy (second period) . The therapy will be adjusted in order to achieve the same
      therapeutic goal for TSH concentrations (greater than or equal to 0.5 less than or equal to
      1.5 mU/L), analogous to that achieved during the first phase of the study (TSH less than or
      equal to 0.5 mU/L difference between T3 and T4 phases). After reaching a 30-day period of
      steady-state replacement, study subjects will be re-admitted to the Clinical Center and the
      previously described evaluation procedures will be repeated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase</measure>
    <time_frame>One month of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol at Levothyroxine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol at Liothyronine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides at Levothyroxine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides at Liothyronine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure at Levothyroxine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Energy Expenditure at Liothyronine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle Mass Index at Levothyroxine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle Mass Index at Liothyronine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A-I at Levothyroxine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A-I at Liothyronine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B at Levothyroxine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B at Liothyronine Treatment Phase</measure>
    <time_frame>One month of therapy.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Thyroid Diseases</condition>
  <arm_group>
    <arm_group_label>Liothyronine and Levothyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypothyroid patients treatment with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine and Levothyroxine</intervention_name>
    <description>Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases</description>
    <arm_group_label>Liothyronine and Levothyroxine</arm_group_label>
    <other_name>T3 and T4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Age greater than or equal to 18 years, male or female.

        History of total or near total thyroidectomy or hypothyroidism on replacement therapy.

        For non-thyroidectomized patients, at least three-year history of replacement therapy (at
        least 1.2 mcg/Kg LT4/body weight), and less than 5% uptake at 24H on (123)I thyroid scan
        while on replacement therapy.

        Written informed consent.

        EXCLUSION CRITERIA:

        BMI less than or equal to 20 or greater than or equal to 30 kg/m(2).

        Metastatic thyroid cancer or history of thyroid cancer with high risk of recurrence
        requiring suppressive thyroid hormone therapy (Singer 1996).

        Significant thyroid residual greater than 1 mL as measured by ultrasound (limited to
        thyroidectomized patients) or greater than 5 percent uptake at 24H on (123)I thyroid scan
        while on replacement therapy (limited to hypothyroid patients not undergone total
        thyroidectomy).

        History or symptoms compatible with cardiovascular disease, including paroxysmal
        supraventricular tachycardia, atrial fibrillation, syncopal episodes or use of prescription
        medications for heart conditions, including antihypertensives.

        Allergy to lidocaine, isoproterenol, TRH, levothyroxine, liothyronine, Tylenol #3,
        oxycodone, nitroglycerin.

        Pregnancy or unwillingness to use non-hormonal contraception during the study.

        Breastfeeding

        Use of hormonal contraceptives or estrogen replacement therapy.

        Use of tobacco (smoking, chewing) for the two weeks preceding the hospital admissions
        (metabolic testing)

        Diabetes mellitus, either type I or II.

        Hypercholesterolemia (serum levels greater than or equal to 240 mg/dL),
        hypertriglyceridemia (plasma levels greater than or equal to 220 mg/dL) and/or use of
        antilipemic therapy.

        Liver disease or ALT serum level greater than two fold the upper laboratory reference
        limit.

        Renal insufficiency or estimated creatinine clearance less than or equal to 50 mL/min.

        Use of medications/supplements/alternative therapies known to alter thyroid function.

        Current history or symptoms compatible with psychosis including major depression (including
        history of hospitalization for depression, history of attempted suicide, history of
        suicidal ideation).

        Use of antipsychotic medications

        History of drug or alcohol abuse within the last 5 years; current use of drugs or alcohol
        (CAGE greater than 3).

        Keloid formation (relative to skeletal muscle and subcutaneous adipose tissue biopsies).

        Current or previous clinically significant (requiring medical/surgical intervention)
        extrathyroidal manifestations of autoimmune thyroid disease (dermopathy, ophthalmopathy,
        arthropathy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kong Y Chen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2005-DK-0119.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Arner P, Bolinder J, Wennlund A, Ostman J. Influence of thyroid hormone level on insulin action in human adipose tissue. Diabetes. 1984 Apr;33(4):369-75.</citation>
    <PMID>6423430</PMID>
  </reference>
  <reference>
    <citation>Bakker SJ, ter Maaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab. 2001 Mar;86(3):1206-11.</citation>
    <PMID>11238510</PMID>
  </reference>
  <reference>
    <citation>Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P, Larsen PR. Characterization of the 5'-flanking and 5'-untranslated regions of the cyclic adenosine 3',5'-monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology. 2000 Jan;141(1):229-37.</citation>
    <PMID>10614643</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2005</study_first_submitted>
  <study_first_submitted_qc>March 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2005</study_first_posted>
  <results_first_submitted>November 12, 2014</results_first_submitted>
  <results_first_submitted_qc>February 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Kong Chen, Ph.D.</investigator_full_name>
    <investigator_title>Clinical Investigator</investigator_title>
  </responsible_party>
  <keyword>Levothyroxine</keyword>
  <keyword>Liothyronine</keyword>
  <keyword>Lipid Metabolism</keyword>
  <keyword>Gluconeogensis</keyword>
  <keyword>Thyrotropin Releasing Hormone</keyword>
  <keyword>Deiodinase</keyword>
  <keyword>Replacement Thyroid Hormone Therapy</keyword>
  <keyword>Thyroidectomy</keyword>
  <keyword>Near Total Thyroidectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from NIH Clinical Center, Bethesda, Maryland, USA between June 2005 and November 2007.</recruitment_details>
      <pre_assignment_details>110 participants inquired through phone; 24 screened, 10 excluded 8 did not meet inclusion criteria and 2 refused participation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liothyronine First, Then Levothyroxine</title>
          <description>Liothyronine (dose of 2.5, 10, or 16 mcg) in first intervention period and Levothyroxine (dose of 5, 10, or 33 mcg) in second intervention period (after washout period)</description>
        </group>
        <group group_id="P2">
          <title>Levothyroxine First, Then Liothyronine</title>
          <description>Levothyroxine (dose of 5, 10, or 33 mcg) in first intervention period and Liothyronine (dose of 2.5, 10, or 16 mcg) in second intervention period (after washout period)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 30 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who completed the study</population>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to receive Levothyroxine first and Liothyronine first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of hypothyroidism</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Thyroid stimulating hormone (TSH)</title>
          <units>mU/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triiodothyronine (T3)</title>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.0" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Free thyroxine (T4)</title>
          <units>ng/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.76" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase</title>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol at Levothyroxine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol at Levothyroxine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase</title>
        <time_frame>One month of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase</title>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.37" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol at Liothyronine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol at Liothyronine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides at Levothyroxine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides at Levothyroxine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides at Liothyronine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides at Liothyronine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Energy Expenditure at Levothyroxine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Energy Expenditure at Levothyroxine Treatment Phase</title>
          <units>kcal/24 hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1201" spread="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Energy Expenditure at Liothyronine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention ArmArm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Energy Expenditure at Liothyronine Treatment Phase</title>
          <units>kcal/24 hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1177" spread="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricle Mass Index at Levothyroxine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle Mass Index at Levothyroxine Treatment Phase</title>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricle Mass Index at Liothyronine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle Mass Index at Liothyronine Treatment Phase</title>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein A-I at Levothyroxine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein A-I at Levothyroxine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein A-I at Liothyronine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein A-I at Liothyronine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B at Levothyroxine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B at Levothyroxine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B at Liothyronine Treatment Phase</title>
        <time_frame>One month of therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liothyronine/Levothyroxine Therapy Intervention Arm</title>
            <description>Hypothyroid patients are treated with Levothyroxine and Liothyronine in 2 crossover, randomized phases</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B at Liothyronine Treatment Phase</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Levothyroxine Period</title>
          <description>Patients at Levothyroxine Period</description>
        </group>
        <group group_id="E2">
          <title>Liothyronine Period</title>
          <description>Patients at Liothyronine Period</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>generalized anxiety disorder</sub_title>
                <description>This adverse event could not be separated between two treatment periods.</description>
                <counts group_id="E1" events="14" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kong Chen</name_or_title>
      <organization>National Institute of Diabetes and Digestive and Kidney Diseases</organization>
      <phone>3014511636</phone>
      <email>chenkong@niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

